Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study

• Status: Unknown status
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized observer-masked cross-over study to compare the intraocular pressure (IOP) reducing effect of latanoprost with bimatoprost in subjects with chronic angle closure glaucoma (CACG) with raised IOP. Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline. The study will be carried out in at least 2 Singapore hospitals.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Singapore National Eye Centre
• Collaborator: Allergan
• Treatments: Bimatoprost; Latanoprost

Criteria

Inclusion Criteria:

1. Unilateral or bilateral CACG

2. Age more than or equal to 40 years old

3. Informed consent obtained at pre-study visit for all patients

Exclusion Criteria:

1. Secondary glaucoma such as uveitic or neovascular glaucoma

2. One eye eligible and fellow eye on unsuitable glaucoma treatment for this trial

3. IOP > 36 mmHg at Pre-study visit

4. Advanced glaucoma at risk of progression. This is defined as vertical cup-disc ratio > 0.9 and/or central visual field loss with a sensitivity of < 10 dB in any of the 4 visual field test points closest to fixation

5. Ocular infection or inflammation (except when related to peripheral iridotomy) within 3 months of the prestudy visit

6. On more than two anti-glaucoma medications

7. Previous intraocular surgery apart from laser peripheral iridotomy

8. Previous trauma to the eye, with angle damage

9. Ocular treatment with a steroid or non-steroidal anti-inflammatory medication within 1 month of the prestudy visit.

10. Use of contact lens.

11. Cornea infection or other cornea abnormalities.

12. Ocular diseases such as dry eye or retinal pathology.

13. Oral medications, such as diuretics, known to affect IOP.

14. Cerebrovascular, hepatic, renal, metabolic disease.

15. Known allergy to benzalkonium, or any other components of latanoprost/bimatoprost.

16. History of non-compliance.

17. Women who are pregnant, lactating, or of childbearing potential and not using adequate contraception.

18. Participated in another therapeutic medication study within the last 1 month.